A phase III, double blind, placebo-controlled trial (MINT trial) (ClinicalTrials.gov, NCT04524273) [128] evaluated inebilizumab in 238 patients with AChR+ and MuSK+ MG [129]. The gene discussed is MUSK; the disease is myasthenia gravis.